Investors facing recent market volatility are encouraged to maintain a long-term perspective, particularly in the healthcare sector, where two promising stocks are emerging as potential strong performers: TransMedics Group (TMDX) and Dexcom (DXCM). TransMedics is innovating in the organ transplant space with its Organ Care System (OCS), which significantly improves organ viability during transport. This technology has led to increased adoption, driving revenue growth—projected to reach $605.5 million in 2025, a 37% increase year-over-year.
Similarly, Dexcom continues to thrive with its continuous glucose monitoring (CGM) devices, which have seen a revenue increase of 16% to $4.7 billion last year. Despite concerns over competition from GLP-1 weight loss medications, Dexcom’s management emphasizes that CGMs and these therapies are often prescribed together, and the company has vast untapped markets globally.
Both companies are strategically positioned for growth, making them attractive options for investors looking to capitalize on long-term trends in healthcare innovation.
Source: fool.com